Diabetes drug could treat leading cause of blindness

May 7, 2012, University of Texas Medical Branch at Galveston

University of Texas Medical Branch at Galveston researchers have discovered that a drug already prescribed to millions of people with diabetes could also have another important use: treating one of the world's leading causes of blindness.

In laboratory rat and cell-culture experiments, the scientists found that , which is commonly used to control in , also substantially reduced the effects of , an of the tissues just below the outer surface of the . Uveitis causes 10 to 15 percent of all cases of blindness in the United States, and is responsible for an even higher proportion of blindness globally. The only treatment now available for the disorder is steroid therapy, which has serious side effects and cannot be used long-term.

"Uveitis has various causes — the most common are infectious diseases and autoimmune disorders— but they all produce inflammation within the eye," said UTMB professor Kota V. Ramana, senior author of a paper on the study now online in the journal Investigative Ophthalmology & Visual Science. "Metformin inhibits the process that causes that inflammation."

The scientists discovered metformin's efficacy when they tested it in rats given an endotoxin that mimicked the inflammatory effects of bacterial infection. The results showed clearly that metformin was a very effective anti-uveitis agent.

"We found that the drug is therapeutic as well as preventive — if we gave our rats the drug beforehand, they didn't develop uveitis, and if we gave it after uveitis had developed, it was therapeutic," said UTMB professor Satish Srivastava, also an author of the IOVS paper. "Metformin's strong anti-inflammatory properties make this possible."

According to the researchers, metformin works by activating an enzyme called AMPK, which in turn damps down the activity of the protein NF-kappa B. The inhibition of NF-kappa B suppresses the production of inflammatory signaling molecules — cytokines and chemokines — needed to initiate and sustain uveitis.

Because metformin is already used so widely as a therapy for diabetes, the UTMB scientists believe that it has a good chance of being rapidly adopted as an anti-uveitis drug.

"I think after a few more pre-clinical studies are done, we can get this drug to patients in a shorter time than usual," Ramana said. "Its safety is already known, so all that we need to see is its efficacy in humans."

Explore further: Medical and surgical treatments equally effective for common inflammatory condition of the eye, study finds

Related Stories

Medical and surgical treatments equally effective for common inflammatory condition of the eye, study finds

August 19, 2011
Patients with uveitis, the fifth leading cause of vision loss in the United States, treated with either systemic anti-inflammatory medicine or with a time-release implant surgically placed inside the eye experienced a similar ...

New study examines risks and benefits of the first line treatment for diabetes

April 10, 2012
Although the drug metformin is considered the gold standard in the management of type 2 diabetes, a study by a group of French researchers published in this week's PLoS Medicine suggests that the long-term benefits of this ...

Diabetes drug can prevent heart disease

March 26, 2012
The widely used diabetes medicine metformin can have protective effects on the heart, reveals a new study conducted at the Sahlgrenska Academy, at the University of Gothenburg, Sweden.

Recommended for you

FDA approves contact lenses that shade the sun

April 13, 2018
The lives of contact lens wearers just got a whole lot easier.

New glaucoma treatment could ease symptoms while you sleep

April 11, 2018
Eye drops developed by UBC researchers could one day treat glaucoma while you sleep - helping to heal a condition that is one of the leading causes of blindness around the world.

Researchers test stem cell-based retinal implant for common cause of vision loss

April 4, 2018
Physicians and researchers at the USC Roski Eye Institute have collaborated with other California institutions to show that a first-in-kind stem cell-based retinal implant is feasible for use in people with advanced dry age-related ...

Post-Ebola cataract surgery can safely restore vision

April 4, 2018
Cataract surgery can be safely performed on Ebola virus disease survivors with impaired vision, Emory Eye Center ophthalmologists and 40 colleagues around the world report.

Older adults with small social networks less likely to get cataract surgery

March 9, 2018
Close family relationships and a strong social network may help older adults see the world better—literally.

A retinal implant that is more effective against blindness

March 9, 2018
EPFL researchers have developed a new type of retinal implant for people who have become blind due to the loss of photoreceptor cells in their retinas. The implant partially restores their visual field and can significantly ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.